The UK and US have concluded a major trade agreement that will ensure no tariffs on British medicine products going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This pledge guarantees that duties on these key exports will remain at zero for a timeframe of the next three years.
This agreement comes after previous threats to hike import taxes on patented drug products, with potential rates floated as high as double the cost.
"This agreement with the United Kingdom reinforces the worldwide climate for innovative medicines and introduces much-needed balance to transatlantic drug exports," a statement noted.
Trade Significance
Medicines represent one of the UK's biggest goods shipped to the America, which is easily the primary market for major British pharmaceutical firms.
Trade data show that in the year to the end of the third quarter, the UK sold medicines valued at £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that span.
"This agreement safeguards jobs, increases investment and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The pact entails several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to double total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds were more than 20%.
Broader Context
This agreement follows a long-running row between the sector and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by assertions that American patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
